Details
Stereochemistry | ACHIRAL |
Molecular Formula | C26H25N3O3S |
Molecular Weight | 459.56 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C(CN1CCN(CC2=CC=C3OCOC3=C2)CC1)N4C5=CC=CC=C5SC6=C4C=CC=C6
InChI
InChIKey=UBAJTZKNDCEGKL-UHFFFAOYSA-N
InChI=1S/C26H25N3O3S/c30-26(29-20-5-1-3-7-24(20)33-25-8-4-2-6-21(25)29)17-28-13-11-27(12-14-28)16-19-9-10-22-23(15-19)32-18-31-22/h1-10,15H,11-14,16-18H2
Molecular Formula | C26H25N3O3S |
Molecular Weight | 459.56 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Fenoverine is a potent musculotropic, the anti-spasmodic agent that restores smooth muscle motility and relieves the distressing symptoms associated with irritable bowel syndrome (IBS) and primary dysmenorrhea. Fenoverine is a non-anticholinergic phenothiazine derivative that may also inhibit calcium channel currents. Fenoverine primarily affects the gastrointestinal tract, bile duct, and female genital organs. Fenoverine has been repeatedly implicated in the occurrence of rhabdomyolysis, a potentially fatal adverse effect, in France. Thes drug has been therefore unavailable in France since December 1995 but commonly used in the treatment of gastrointestinal spasmodic disorders in Taiwan.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0070588 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3113828 |
|||
Target ID: GO:0005262 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1786520 |
7.5 µM [IC50] |
PubMed
Title | Date | PubMed |
---|---|---|
Formulation and evaluation of rapidly disintegrating fenoverine tablets: effect of superdisintegrants. | 2007 Nov |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
Formulation and evaluation of multiple tablets as a biphasic gastroretentive floating drug delivery system for fenoverine. | 2010 Mar |
|
In vitro evaluation of domperidone mouth dissolving tablets. | 2010 Nov |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:38:25 GMT 2023
by
admin
on
Sat Dec 16 17:38:25 GMT 2023
|
Record UNII |
N274ZQ6PZJ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29698
Created by
admin on Sat Dec 16 17:38:25 GMT 2023 , Edited by admin on Sat Dec 16 17:38:25 GMT 2023
|
||
|
WHO-ATC |
A03AX05
Created by
admin on Sat Dec 16 17:38:25 GMT 2023 , Edited by admin on Sat Dec 16 17:38:25 GMT 2023
|
||
|
WHO-VATC |
QA03AX05
Created by
admin on Sat Dec 16 17:38:25 GMT 2023 , Edited by admin on Sat Dec 16 17:38:25 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB07580MIG
Created by
admin on Sat Dec 16 17:38:25 GMT 2023 , Edited by admin on Sat Dec 16 17:38:25 GMT 2023
|
PRIMARY | |||
|
FENOVERINE
Created by
admin on Sat Dec 16 17:38:25 GMT 2023 , Edited by admin on Sat Dec 16 17:38:25 GMT 2023
|
PRIMARY | |||
|
100000081302
Created by
admin on Sat Dec 16 17:38:25 GMT 2023 , Edited by admin on Sat Dec 16 17:38:25 GMT 2023
|
PRIMARY | |||
|
C048314
Created by
admin on Sat Dec 16 17:38:25 GMT 2023 , Edited by admin on Sat Dec 16 17:38:25 GMT 2023
|
PRIMARY | |||
|
1156
Created by
admin on Sat Dec 16 17:38:25 GMT 2023 , Edited by admin on Sat Dec 16 17:38:25 GMT 2023
|
PRIMARY | |||
|
37561-27-6
Created by
admin on Sat Dec 16 17:38:25 GMT 2023 , Edited by admin on Sat Dec 16 17:38:25 GMT 2023
|
PRIMARY | |||
|
C65660
Created by
admin on Sat Dec 16 17:38:25 GMT 2023 , Edited by admin on Sat Dec 16 17:38:25 GMT 2023
|
PRIMARY | |||
|
253-552-1
Created by
admin on Sat Dec 16 17:38:25 GMT 2023 , Edited by admin on Sat Dec 16 17:38:25 GMT 2023
|
PRIMARY | |||
|
24855
Created by
admin on Sat Dec 16 17:38:25 GMT 2023 , Edited by admin on Sat Dec 16 17:38:25 GMT 2023
|
PRIMARY | RxNorm | ||
|
N274ZQ6PZJ
Created by
admin on Sat Dec 16 17:38:25 GMT 2023 , Edited by admin on Sat Dec 16 17:38:25 GMT 2023
|
PRIMARY | |||
|
CHEMBL1512949
Created by
admin on Sat Dec 16 17:38:25 GMT 2023 , Edited by admin on Sat Dec 16 17:38:25 GMT 2023
|
PRIMARY | |||
|
3288
Created by
admin on Sat Dec 16 17:38:25 GMT 2023 , Edited by admin on Sat Dec 16 17:38:25 GMT 2023
|
PRIMARY | |||
|
DB13042
Created by
admin on Sat Dec 16 17:38:25 GMT 2023 , Edited by admin on Sat Dec 16 17:38:25 GMT 2023
|
PRIMARY | |||
|
72098
Created by
admin on Sat Dec 16 17:38:25 GMT 2023 , Edited by admin on Sat Dec 16 17:38:25 GMT 2023
|
PRIMARY | |||
|
m5283
Created by
admin on Sat Dec 16 17:38:25 GMT 2023 , Edited by admin on Sat Dec 16 17:38:25 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID8046296
Created by
admin on Sat Dec 16 17:38:25 GMT 2023 , Edited by admin on Sat Dec 16 17:38:25 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |